Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: Disclosed is a method and system to reduce user equipment (UE) battery consumption and efficiently utilize uplink hybrid automatic repeat request (HARQ) memory, including sending uplink data to a base station and saving a backup copy of the uplink data in an uplink HARQ buffer, receiving an acknowledgement from the base station indicating that the uplink data has been received, measuring a HARQ retransmission time required to retransmit the uplink data to the base station after receiving the acknowledgement, comparing the measured HARQ retransmission time to a remaining discontinuous reception cycle, and removing the uplink data from the uplink HARQ buffer after expiration of an inactivity timer and switching the UE to a sleep mode based on the comparison.

Abstract: Disclosed is a method and system to reduce user equipment (UE) battery consumption and efficiently utilize uplink hybrid automatic repeat request (HARQ) memory, including sending uplink data to a base station and saving a backup copy of the uplink data in an uplink HARQ buffer, receiving an acknowledgement from the base station indicating that the uplink data has been received, measuring a HARQ retransmission time required to retransmit the uplink data to the base station after receiving the acknowledgement, comparing the measured HARQ retransmission time to a remaining discontinuous reception cycle, and removing the uplink data from the uplink HARQ buffer after expiration of an inactivity timer and switching the UE to a sleep mode based on the comparison.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution.

Abstract: Disclosed is a method and system to reduce user equipment (UE) battery consumption and efficiently utilize uplink hybrid automatic repeat request (HARQ) memory, including sending uplink data to a base station and saving a backup copy of the uplink data in an uplink HARQ buffer, receiving an acknowledgement from the base station indicating that the uplink data has been received, measuring a HARQ retransmission time required to retransmit the uplink data to the base station after receiving the acknowledgement, comparing the measured HARQ retransmission time to a remaining discontinuous reception cycle, and removing the uplink data from the uplink HARQ buffer after expiration of an inactivity timer and switching the UE to a sleep mode based on the comparison.

Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Abstract: Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution.